INmune Bio Stock Rises As Small-Cap Shows Promise In Alzheimer’s Disease

INmune Bio (INMB) said its experimental Alzheimer’s drug improved markers of inflammation in the brain and INMB stock rose higher.


Researchers say a protein called phospho tau, or pTau, could be a key indicator of Alzheimer’s disease. In a study of Alzheimer’s patients, INmune’s drug called pegipanermin lowered two forms of pTau. The drug also increased markers that show improvement in deep brain tissue called white matter.

On today’s stock market, INMB stock inched 0.6% to 24.02. Earlier, shares popped as much as 10.9%.

INMB Stock Rises On Biomarker Data

There are several forms of phospho tau. After weekly injections of pegipanermin for three months, the patients showed a 46% reduction in pTau217 and a lesser reduction in pTau181. Researchers extracted the phospho tau levels from patients’ cerebral spinal fluid.

The presence of pTau181 is standard in Alzheimer’s disease. But INmune says decreasing the level of pTau217 could be more important for controlling inflammation in the brain. Many researchers believe inflammation in the brain is the primary culprit behind Alzheimer’s disease. The improvement in pTau levels could be a boon for INMB stock.

White Matter Improvement

Further, pegipanermin-treated patients showed a 16% increase in a biomarker related to white matter improvement. Many of the nerve fibers in the brain’s white matter are surrounded by sheaths known as myelin. But these sheaths can break down. After receiving pegipanermin patients showed evidence that some of their myelin sheaths had regenerated, a process called remyelination.

This could “potentially translate to improvements in cognition,” Maxim Group analyst Jason McCarthy said in a report to clients. He reiterated his buy rating and 42 price target on INMB stock. The company is set to begin a Phase 2 study in 200 mild Alzheimer’s patients before year’s end.

The news took INMB stock to a two-month high on Thursday. Shares have a strong Relative Strength Rating of 97 out of a best-possible 99. This puts INMB stock in the leading 3% of all stocks in terms of 12-month performance, according to IBD Digital.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


AbbVie Stock: Why A New FDA Order Hit It Harder Than Rivals Pfizer, Lilly

Why InMode Stock Is Looking Picture Perfect Amid The Burgeoning Selfie Culture

IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks

Want To Get Quick Profits And Avoid Big Losses? Try SwingTrader

Learn How To Time The Market With IBD’s ETF Market Strategy

Most Related Links :
Business News Governmental News Finance News

Need Your Help Today. Your $1 can change life.

[charitable_donation_form campaign_id=57167]

Source link

Back to top button